NEW YORK — Elysium Health said on Thursday that it has acquired the exclusive rights to DNA methylation biomarkers of aging and cellular senescence from Yale University.
Financial and other terms of the license were not disclosed.
New York City-based Elysium markets anti-aging supplements and a direct-to-consumer DNA methylation analysis kit called Index that is designed to provide information about biological age to guide lifestyle changes.
According to Elysium, the licensed biomarkers were developed by Yale researcher Morgan Levine, who joined the company in 2019 as its bioinformatics advisor and leads the development of Index. The company said that it intends to incorporate a cellular senescence measure into the Index product later this year.